ACURA Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>AP</div>
ACUR -- USA Stock  

USD 0.22  0.01  4.35%

As many baby boomers are indifferent towards healthcare space, it makes sense to sum up ACURA PHARMACEUTICALS INC against current market trends. As we have suggested previously, ACURA PHARMACEUTICALS is beginning its fall as retail investors shift to be more bearish due to the increased sector volatility. ACURA PHARMACEUTICALS INC barely shadows the market. The returns on investing in ACURA PHARMACEUTICALS and the market returns of the last few months appear uncorrelated to each other. Invariable basic indicators of the enterprise may connote signs of short-term price drift for retail investors. ACURA PHARMACEUTICALS INC is scheduled to announce its earnings tomorrow.
Published over a month ago
View all stories for ACURA PHARMACEUTICALS | View All Stories
Should I shadow ACURA PHARMACEUTICALS INC (OTC:ACUR) retail investors?
ACURA PHARMACEUTICALS INC's average rating is Strong Buy from 1 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on ACURA PHARMACEUTICALS market sentiment investors' perception of the future value of ACURA. Let us look at a few aspects of ACURA technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of ACURA PHARMACEUTICALS INC. In general, we focus on analyzing ACURA PHARMACEUTICALS stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ACURA PHARMACEUTICALS's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of ACURA PHARMACEUTICALS's intrinsic value. In addition to deriving basic predictive indicators for ACURA PHARMACEUTICALS, we also check how macroeconomic factors affect ACURA PHARMACEUTICALS price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of ACURA PHARMACEUTICALS's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of ACURA PHARMACEUTICALS in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as ACURA PHARMACEUTICALS. Your research has to be compared to or analyzed against ACURA PHARMACEUTICALS's peers to derive any actionable benefits. When done correctly, ACURA PHARMACEUTICALS's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in ACURA PHARMACEUTICALS INC.

Watch out for price decline

Please consider monitoring ACURA PHARMACEUTICALS on a daily basis if you are holding a position in it. ACURA PHARMACEUTICALS is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as ACURA PHARMACEUTICALS stock to be traded above the $1 level to remain listed. If ACURA PHARMACEUTICALS stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How does ACURA Stands against Peers?

Analyzing ACURA PHARMACEUTICALS competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to ACURA PHARMACEUTICALS across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out ACURA PHARMACEUTICALS Competition Details

How ACURA utilizes its cash?

To perform a cash flow analysis of ACURA PHARMACEUTICALS, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash ACURA PHARMACEUTICALS is receiving and how much cash it distributes out in a given period. The ACURA PHARMACEUTICALS cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. ACURA PHARMACEUTICALS Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. ACURA PHARMACEUTICALS reported last year Net Cash Flow from Operations of (556,200)

Closer look at ACURA PHARMACEUTICALS Variance

ACURA PHARMACEUTICALS INC has current Variance of 108.34. Variance is another measure of security risk that shows the amount of dispersion of equity returns around their mean value. Variance is calculated as the average squared deviations from the mean. Evaluating a set of investment alternatives one can use variance to help determine the volatility when purchasing a specific security. Similar to Standard Deviation, the variance is a measure of how far a set of numbers is spread out around its mean.

Variance is also a measure of stock volatility and can help determine the risk an investor might take on when purchasing a specific security. A relatively big variance indicates that the daily prices or returns are far from the mean and a small variance indicates that they are located around the mean.

Variance 
 = 
SUM(RET DEV)2 
 = 
108.34
SUM = Summation notation
RET DEV = Actual returns deviation over selected period
N = Number of points for the period
Let's now compare ACURA PHARMACEUTICALS Variance to its closest peers:
ACUR
EQ
NK
DMAC
DNLI
ACUR108.34
EQ66.21
NK36.31
DMAC25.43
DNLI16.22

Is ACURA PHARMACEUTICALS getting woozy?

Latest Skewness is up to -0.09. Price may fall again. As of the 26th of November, ACURA PHARMACEUTICALS shows the Mean Deviation of 7.34, coefficient of variation of 3039.29, and Market Risk Adjusted Performance of 114.65. ACURA PHARMACEUTICALS INC technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices. Put another way, you can use this information to find out if the entity will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for ACURA PHARMACEUTICALS INC, which can be compared to its rivals. Please confirm ACURA PHARMACEUTICALS INC variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if ACURA PHARMACEUTICALS INC is priced favorably, providing market reflects its regular price of 0.21 per share. As ACURA PHARMACEUTICALS INC appears to be a penny stock we also recommend to validate its total risk alpha numbers.

Our Final Take On ACURA PHARMACEUTICALS

While some other firms within the drug manufacturers?specialty & generic industry are still a little expensive, even after the recent corrections, ACURA PHARMACEUTICALS may offer a potential longer-term growth to retail investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor exit any shares of ACURA PHARMACEUTICALS at this time. The ACURA PHARMACEUTICALS INC risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to ACURA PHARMACEUTICALS.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of ACURA PHARMACEUTICALS INC. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com